evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,293 questions · 2,395 findings · 172 reviews · Gut

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 420 · 17.5%GRADE not reported 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%

Intervention not reported

Serious adverse events · patients with pancreatic pseudocysts

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Open surgical drainage versus EUS‐guided drainage Scale from: 0 to 100. Higher indicates better · patients with pancreatic pseudocysts
1 finding from 1 review

Intervention not reported

Adverse events · patients with pancreatic pseudocysts

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Endoscopic drainage versus EUS‐guided drainage · patients with pancreatic pseudocysts

It is very uncertain whether the intervention changes endoscopic drainage versus EUS‐guided drainage (very low certainty).

1 finding from 1 review

Intervention not reported

EUS‐guided drainage with nasocystic drainage versus EUS‐guided drainage · patients with pancreatic pseudocysts

The intervention may leads to lower EUS‐guided drainage with nasocystic drainage versus EUS‐guided… (low certainty).

1 finding from 1 review

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Progression‐free survival · people with advanced gastric cancer

Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).

1 finding from 1 review

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Overall response rate Duration of · people with advanced gastric cancer

Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in overall response rate Duration of compared with chemotherapy alone (low certainty).

1 finding from 1 review

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Adverse event (any) Duration of · people with advanced gastric cancer

Summary of findings: Molecular‐targeted therapy plus chemotherapy probably leads to higher adverse event (any) Duration of compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Severe adverse event (grade ≥ 3 ) Duration of · people with advanced gastric cancer

Summary of findings: Molecular‐targeted therapy plus chemotherapy probably leads to higher severe adverse event (grade ≥ 3 ) Duration of compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Non‐surgical vs surgical treatment of oesophageal cancer (primary outcomes)

Short‐term mortality All‐cause mortality either in‐hospital or within 3 months · patients with oesophageal cancer

It is very uncertain whether non‐surgical changes short‐term mortality All‐cause mortality either in‐hospital or… compared with surgical treatment of oesophageal cancer (primary outcomes) (very low certainty).

1 finding from 1 review

Non‐surgical vs surgical treatment of oesophageal cancer (primary outcomes)

Long‐term recurrence (> 5 years) · patients with oesophageal cancer

It is very uncertain whether non‐surgical changes long‐term recurrence (binary outcome) Local recurrence, surgical… compared with surgical treatment of oesophageal cancer (secondary outcomes) (very low certainty).

1 finding from 1 review

Non‐surgical vs surgical treatment of oesophageal cancer (primary outcomes)

Long‐term recurrence (maximal · patients with oesophageal cancer

Non‐surgical showed no clear difference in long‐term recurrence (time‐to‐event outcome) Local recurrence,… compared with surgical treatment of oesophageal cancer (secondary outcomes) (low certainty).

1 finding from 1 review

Non‐surgical vs surgical treatment of oesophageal cancer (primary outcomes)

Proportion with any adverse event within 3 months Any adverse event within 3 months of any severity · patients with oesophageal cancer

It is very uncertain whether non‐surgical changes proportion with any adverse event within 3 months Any adverse event… compared with surgical treatment of oesophageal cancer (secondary outcomes) (very low certainty).

1 finding from 1 review

Non‐surgical vs surgical treatment of oesophageal cancer (primary outcomes)

Long‐term mortality (binary outcome) All‐cause mortality for the duration of · patients with oesophageal cancer

Non‐surgical showed no clear difference in long‐term mortality (binary outcome) All‐cause mortality for the… compared with surgical treatment of oesophageal cancer (primary outcomes) (low certainty).

2 findings from 1 review

Non‐surgical vs surgical treatment of oesophageal cancer (primary outcomes)

Long‐term mortality (time‐to‐event outcome): chemoradiotherapy versus surgery All‐cause mortality for the duration of · patients with oesophageal cancer

Non‐surgical showed no clear difference in long‐term mortality (time‐to‐event outcome): chemoradiotherapy… compared with surgical treatment of oesophageal cancer (primary outcomes) (low certainty).

2 findings from 1 review